Skip to main content
Evidence Snapshot

Leukotriene B4 receptor 1

CHEMBL3911 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T23:51:42Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3911
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Leukotriene B4 receptor 1 as ChEMBL target CHEMBL3911, mapped to UniProt Q15722. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Leukotriene B4 receptor 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3911
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q15722
Leukotriene B4 receptor 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Leukotriene B4 receptor 1 matters

As of 2026-09-13

Leukotriene B4 receptor 1 is reviewed as Leukotriene B4 receptor 1 (UniProt Q15722); Leukotriene B4 receptor 1 shows clinical signal disease relevance led by asthma. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 1 approved drug, 701 compounds, and 190 assays, with lead potency reaching pChEMBL 10.4.

Disease context
asthma

Leukotriene B4 receptor 1 shows clinical signal disease relevance led by asthma. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include AMELUBANT.

Start review with asthma because it currently carries clinical signal support. Linked drugs include AMELUBANT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Clinical signal 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 1 approved drug, 701 compounds, and 190 assays for this target. The dominant activity type is IC50. CHEMBL292782 is the current potency anchor at pChEMBL 10.4.

Use CHEMBL292782 as the tractability anchor when discussing potency (pChEMBL 10.4).

Activity source · ChEMBL 36 via Core Engine
1 approved pChEMBL 10.4
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Leukotriene B4 receptor 1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q15722, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why asthma is currently treated as clinical signal support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

701
Total Compounds
190
Total Assays
1
Approved Drugs
IC50: 384.0, KI: 193.0, EC50: 63.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL292782
 10.4 Ki —
No preferred name
CHEMBL1099326
 10.2 IC50 —
No preferred name
CHEMBL62265
 10.1 Ki —
No preferred name
CHEMBL422388
 10.0 IC50 —
No preferred name
CHEMBL340460
 10.0 Ki —

Approved Drugs

Structure Compound First Approval
ZILEUTON
CHEMBL93
 1996
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T23:51:42Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3911